SEC Comment Letter 0000000000-24-011306 to ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V.
Date: Oct. 7, 2024 · CIK: 0001612940 · Accession: 0000000000-24-011306
AI Filing Summary & Sentiment
File numbers found in text: 333-282419
Letter
October 7, 2024 Daniel de Boer Chief Executive Officer ProQR Therapeutics N.V. 2333 CK Leiden The Netherlands Re:ProQR Therapeutics N.V. Registration Statement on Form F-3 Filed September 30, 2024 File No. 333-282419 Dear Daniel de Boer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mitchell S. Bloom, Esq.
Show Raw Text
October 7, 2024
Daniel de Boer
Chief Executive Officer
ProQR Therapeutics N.V.
2333 CK Leiden
The Netherlands
Re:ProQR Therapeutics N.V.
Registration Statement on Form F-3
Filed September 30, 2024
File No. 333-282419
Dear Daniel de Boer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mitchell S. Bloom, Esq.